Table Info

Table 1.

Selected anticancer effects of SAB on tumor cell lines

Type of cancer	Model/cell line	Morphological effects	Mechanisms of action	References
Oral cancer	CAL27, SCC4, Leuk1	Apoptosis, inhibits cell growth, anti-angiogenesis	↓HIF-1α, ↓TNFα, ↓MMP9, ↓Tenascin-C, ↓Osteopontin, ↓TGFβ, ↓Cox-2, ↓HGF, ↓MMP2, ↑THBS2	[75, 76]
Oral cancer	CAL27, HN4, and Leuk1	Apoptosis, inhibits cell growth, modulates Warburg effect	↓MMP, ↓PI3K/Akt/HIF-α	[123]
Leukemia	HL-60	Apoptosis, inhibits cell growth	-	[125]
Cervical cancer	Hela cells SAB + ATO	Apoptosis, inhibits cell growth	↓pro-caspase 3, ↑PARP cleavage	[96]
Retinoblastoma	HXO-RB44	Apoptosis, cell volume shrinkage, chromatics agglutination, inhibits cell growth, cell cycle arrest at S phase	↑caspase 3	[117]

↑ increases expression, ↓ decreases expression

Declarations

Author contributions

This manuscript has been written by IS, ZA and SB. It was edited by BM, ASN and RM. All authors have read and agreed to the published version of the manuscript.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work was supported by Higher Education Commission of Pakistan (HEC) grant. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. [DOI] [PubMed]

World Health Organization WHO report on cancer: setting priorities, investing wisely and providing care for all. 2020. https://www.who.int/publications/i/item/who-report-on-cancer-setting-priorities-investing-wisely-and-providing-care-for-all. [Last accessed on 30 Apr 2020].

Fidler MM, Bray F, Soerjomataram I. The global cancer burden and human development: a review. Scand J Public Health. 2018;46:27–36. [DOI]

Ramachandran L, Manu KA, Shanmugam MK, Li F, Siveen KS, Vali S, et al. Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor γ activation pathway in gastric cancer. J Biol Chem. 2012;287:38028–40. [DOI] [PubMed] [PMC]

Mishra S, Verma SS, Rai V, Awasthee N, Chava S, Hui KM, et al. Long non-coding RNAs are emerging targets of phytochemicals for cancer and other chronic diseases. Cell Mol Life Sci. 2019;76:1947–66. [DOI] [PubMed]

Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, et al. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1. J Cell Physiol. 2012;227:2184–95. [DOI] [PubMed]

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. [DOI] [PubMed]

Manu KA, Shanmugam MK, Ramachandran L, Li F, Siveen KS, Chinnathambi A, et al. Isorhamnetin augments the anti-tumor effect of capeciatbine through the negative regulation of NF-κB signaling cascade in gastric cancer. Cancer Lett. 2015;363:28–36. [DOI] [PubMed]

Raphael MJ, Siemens R, Peng Y, Vera-Badillo FE, Booth CM. Volume of systemic cancer therapy delivery and outcomes of patients with solid tumors: a systematic review and methodologic evaluation of the literature. J Cancer Policy. 2020;23:100215. [DOI]

10.

Mohan CD, Rangappa S, Preetham HD, Chandra Nayak S, Gupta VK, Basappa S, et al. Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature. Semin Cancer Bio. 2020;[Epub ahead of print]. [DOI]

11.

Loh CY, Arya A, Naema AF, Wong WF, Sethi G, Looi CY. Signal transducer and activator of transcription (STATs) proteins in cancer and inflammation: functions and therapeutic implication. Front Oncol. 2019;9:48. [DOI] [PubMed] [PMC]

12.

Prasannan R, Kalesh KA, Shanmugam MK, Nachiyappan A, Ramachandran L, Nguyen AH, et al. Key cell signaling pathways modulated by zerumbone: role in the prevention and treatment of cancer. Biochem Pharmacol. 2012;84:1268–76. [DOI] [PubMed]

13.

Shanmugam MK, Kannaiyan R, Sethi G. Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer. Nutr Cancer. 2011;63:161–73. [DOI] [PubMed]

14.

Kroschinsky F, Stölzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017;21:89. [DOI] [PubMed] [PMC]

15.

Magge RS, DeAngelis LM. The double-edged sword: neurotoxicity of chemotherapy. Blood Rev. 2015;29:93–100. [DOI] [PubMed] [PMC]

16.

Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14;10. [DOI] [PubMed] [PMC]

17.

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836–46. [DOI] [PubMed] [PMC]

18.

Patwardhan B, Gautam M. Botanical immunodrugs: scope and opportunities. Drug Discov Today. 2005;10:495–502. [DOI] [PubMed] [PMC]

19.

Manu KA, Shanmugam MK, Li F, Chen L, Siveen KS, Ahn KS, et al. Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products. J Mol Med (Berl). 2014;92:267–76. [DOI] [PubMed]

20.

Jung YY, Lee JH, Nam D, Narula AS, Namjoshi OA, Blough BE, et al. Anti-myeloma effects of icariin are mediated through the attenuation of JAK/STAT3-dependent signaling cascade. Front Pharmacol. 2018;9:531. [DOI] [PubMed] [PMC]

21.

Li F, Shanmugam MK, Siveen KS, Wang F, Ong TH, Loo SY, et al. Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers. Oncotarget. 2015;6:5147–63. [DOI] [PubMed] [PMC]

22.

Zhang J, Ahn KS, Kim C, Shanmugam MK, Siveen KS, Arfuso F, et al. Nimbolide-induced oxidative stress abrogates STAT3 signaling cascade and inhibits tumor growth in transgenic adenocarcinoma of mouse prostate model. Antioxid Redox Signal. 2016;24:575–89. [DOI] [PubMed]

23.

Lee JH, Chiang SY, Nam D, Chung WS, Lee J, Na YS, et al. Capillarisininhibitsconstitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases. Cancer Lett. 2014;345:140–8. [DOI] [PubMed]

24.

Patridge E, Gareiss P, Kinch MS, Hoyer D. An analysis of FDA-approved drugs: natural products and their derivatives. Drug Discov Today. 2016;21:204–7. [DOI] [PubMed]

25.

Siveen KS, Ahn KS, Ong TH, Shanmugam MK, Li F, Yap WN, et al. γ-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model. Oncotarget. 2014;5:1897–911. [DOI] [PubMed] [PMC]

26.

Patel SM, Nagulapalli Venkata KC, Bhattacharyya P, Sethi G, Bishayee A. Potential of neem (Azadirachta indica L.) for prevention and treatment of oncologic diseases. Semin Cancer Biol. 2016;40–41:100–15. [DOI]

27.

Dai X, Zhang J, Arfuso F, Chinnathambi A, Zayed ME, Alharbi SA, et al. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. Exp Biol Med (Maywood). 2015;240:760–73. [DOI] [PubMed] [PMC]

28.

Li YG, Song L, Liu M, Hu ZB, Wang ZT. Advancement in analysis of Salviae miltiorrhizae Radix et Rhizoma (Danshen). J Chromatogr A. 2009;1216:1941–53. [DOI] [PubMed]

29.

Zhou L, Zuo Z, Chow MSS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 2005;45:1345–59. [DOI] [PubMed]

30.

Liu J, Shen HM, Ong CN. Salvia miltiorrhiza inhibits cell growth and induces apoptosis in human hepatoma HepG2 cells. Cancer Lett. 2000;153:85–93. [DOI] [PubMed]

31.

Ma L, Tang L, Yi Q. Salvianolic acids: potential source of natural drugs for the treatment of fibrosis disease and cancer. Front Pharmacol. 2019;10:97. [DOI] [PubMed] [PMC]

32.

Cheng TO. Cardiovascular effects of Danshen. Int J Cardiol. 2007;121:9–22. [DOI] [PubMed]

33.

Lin TH, Hsieh CL. Pharmacological effects of Salvia miltiorrhiza (Danshen) on cerebral infarction. Chin Med. 2010;5:22 [DOI] [PubMed] [PMC]

34.

Lien EJ, Ren S, Bui HH, Wang R. Quantitative structure-activity relationship analysis of phenolic antioxidants. Free Radic Biol Med. 1999;26:285–94. [DOI] [PubMed]

35.

Li MH, Chen JM, Peng Y, Xiao PG. Distribution of phenolic acids in Chinese salvia plants. World Sci Technol. 2008;10:46–52. [DOI]

36.

Wang X, Morris-Natschke SL, Lee KH. New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med Res Rev. 2007;27:133–48. [DOI] [PubMed]

37.

Du G, Song J, Du L, Zhang L, Qiang G, Wang S, et al. Chemical and pharmacological research on the polyphenol acids isolated from Danshen: a review of salvianolic acids. Adv Pharmacol. 2020;87;1–41. [DOI] [PubMed]

38.

Cao W, Guo XW, Zheng HZ, Li DP, Jia GB, Wang J. Current progress of research on pharmacologic actions of salvianolic acid B. Chin J Integr Med. 2012;18:316–20. [DOI] [PubMed]

39.

Tang MK, Ren DC, Zhang JT, Du GH. Effect of salvianolic acids from Radix Salviae miltiorrhizae on regional cerebral blood flow and platelet aggregation in rats. Phytomed. 2002;9:405–9. [DOI]

40.

Durairajan SSK, Yuan Q, Xie L, Chan WS, Kum WF, Koo I, et al. Salvianolic acid B inhibits Aβ fibril formation and disaggregates preformed fibrils and protects against Aβ-induced cytotoxicty. Neurochem Int. 2008;52:741–50. [DOI] [PubMed]

41.

Ai CB, Li LN. Stereostructure of salvianolic acid B and isolation of salvianolic acid C from Salvia miltiorrhiza. J Nat Prod. 1988;51:145–9. [DOI]

42.

Garcia CSC, Menti C, Lambert APF, Barcellos T, Moura S, Calloni C, et al. Pharmacological perspectives from Brazilian Salvia officinalis (Lamiaceae): antioxidant, and antitumor in mammalian cells. An Acad Bras Cienc. 2016;88:281–92. [DOI] [PubMed]

43.

Huang YS, Zhang JT. Antioxidative effect of three water-soluble components isolated from Salvia miltiorrhiza in vitro. Acta pharmaceutica Sinica. 1992;27:96–100. [PubMed]

44.

Zhao GR, Zhang HM, Ye TX, Xiang ZJ, Yuan YJ, Guo ZX, et al. Characterization of the radical scavenging and antioxidant activities of danshensu and salvianolic acid B. Food Chem Toxicol. 2008;46:73–81. [DOI] [PubMed]

45.

Shanbhag VKL. Tanshinones in management of oral submucous fibrosis and oral squamous cell carcinoma. Oncobiology and Targets. 2017;04:456966. [DOI]

46.

Shi M, Huang F, Deng C, Wang Y, Kai G. Bioactivities, biosynthesis and biotechnological production of phenolic acids in Salvia miltiorrhiza. Crit Rev Food Sci Nutr. 2019;59:953–64. [DOI] [PubMed]

47.

Petersen M, Häusler E, Karwatzki B, Meinhard J. Proposed biosynthetic pathway for rosmarinic acid in cell cultures of Coleus blumei Benth. Planta. 1993;189:10–4. [DOI]

48.

Wang FM, Li L, Liu XP, Wang XR, Li XC. Extraction of Salvianolic acid B from Danshen (Salvia Miltiorrhiza Bge.) and determination by HPLC method. Res Pract Chin Med. 2004;S1:62–4. Chinese.

49.

Dong J, Liu Y, Liang Z, Wang W. Investigation on ultrasound-assisted extraction of salvianolic acid B from Salvia miltiorrhiza root. Ultrason Sonochem. 2010;17:61–5. [DOI] [PubMed]

50.

Fouad YA, Aanei C. Revisiting the hallmarks of cancer. Am J Cancer Res. 2017;7:1016–36. [PubMed] [PMC]

51.

Qin T, Rasul A, Sarfraz A, Sarfraz I, Hussain G, Anwar H, et al. Salvianolic acid A & B: potential cytotoxic polyphenols in battle against cancer via targeting multiple signaling pathways. Int J Biol Sci. 2019;15:2256–64. [DOI] [PubMed] [PMC]

52.

Kirtonia A, Sethi G, Garg M. The multifaceted role of reactive oxygen species in tumorigenesis. Cell Mol Life Sci. 2020;[Epub ahead of print]. [DOI]

53.

Aggarwal V, Tuli HS, Varol A, Thakral F, Yerer MB, Sak K, et al. Role of reactive oxygen species in cancer progression: molecular mechanisms and recent advancements. Biomolecules. 2019;9:735. [DOI]

54.

Dai X, Wang L, Deivasigamni A, Looi CY, Karthikeyan C, Trivedi P, et al. A novel benzimidazole derivative, MBIC inhibits tumor growth and promotes apoptosis via activation of ROS-dependent JNK signaling pathway in hepatocellular carcinoma. Oncotarget. 2017;8:12831–42. [DOI] [PubMed] [PMC]

55.

Kim C, Lee SG, Yang WM, Arfuso F, Um JY, Kumar AP, et al. Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model. Cancer Lett. 2018;431:123–41. [DOI] [PubMed]

56.

Yan F. Effects of salvianolic acid B on growth inhibition and apoptosis induction of ovarian cancer SKOV3. Eur J Gynaecol Oncol. 2016;1;37:653–6. [DOI]

57.

Hao Y, Xie T, Korotcov A, Zhou Y, Pang X, Shan L, et al. Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways. Int J Cancer. 2009;124:2200–9. [DOI] [PubMed] [PMC]

58.

Zhao Y, Hao Y, Ji H, Fang Y, Guo Y, Sha W, et al. Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo. Cancer Prev Res (Phila). 2010;3:787–96. [DOI] [PubMed] [PMC]

59.

Lee JH, Kim C, Um JY, Sethi G, Ahn KS. Casticin-induced inhibition of cell growth and survival are mediated through the dual modulation of Akt/mTOR signaling cascade. Cancers (Basel). 2019;11:254. [DOI]

60.

Gong L, Di C, Xia X, Wang J, Chen G, Shi J, et al. AKT/mTOR signaling pathway is involved in salvianolic acid B-induced autophagy and apoptosis in hepatocellular carcinoma cells. Int J Oncol. 2016;49:2538–48. [DOI] [PubMed]

61.

Ong PS, Wang LZ, Dai X, Tseng SH, Loo SJ, Sethi G. Judicious toggling of mTOR activity to combat insulin resistance and cancer: current evidence and perspectives. Front Pharmacol. 2016;7:395. [DOI] [PubMed] [PMC]

62.

Mohan CD, Srinivasa V, Rangappa S, Mervin L, Mohan S, Paricharak S, et al. Trisubstituted-imidazoles induce apoptosis in human breast cancer cells by targeting the oncogenic PI3K/Akt/mTOR signaling pathway. PLoS One. 2016;11:e0153155. [DOI] [PubMed] [PMC]

63.

Jing Z, Fei W, Zhou J, Zhang L, Chen L, Zhang X, et al. Salvianolic acid B, a novel autophagy inducer, exerts antitumor activity as a single agent in colorectal cancer cells. Oncotarget. 2016;7:61509–19. [DOI] [PubMed] [PMC]

64.

Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008;451:1069–75. [DOI] [PubMed] [PMC]

65.

Rosenfeldt MT, Ryan KM. The multiple roles of autophagy in cancer. Carcinogenesis. 2011;32:955–63. [DOI] [PubMed] [PMC]

66.

Wang C, Cigliano A, Jiang L, Li X, Fan B, Pilo MG, et al. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice. Hepatology. 2015;61:200–13. [DOI] [PubMed] [PMC]

67.

Xia Y, Shen S, Verma IM. NF-κB, an active player in human cancers. Cancer Immunol Res. 2014;2:823–30. [DOI] [PubMed] [PMC]

68.

Puar YR, Shanmugam MF, Fan L, Arfuso F, Sethi G, Tergaonkar V. Evidence for the involvement of the master transcription factor NF-κB in cancer initiation and progression. Biomedicines. 2018;6:82. [DOI]

69.

Sethi G, Ahn KS, Sung B, Aggarwal BB. Pinitol targets nuclear factor-κB activation pathway leading to inhibition of gene products associated with proliferation, apoptosis, invasion, and angiogenesis. Mol Cancer Ther. 2008;7:1604–14. [DOI] [PubMed]

70.

Chua AWL, Hay HS, Rajendran P, Shanmugam MK, Li F, Bist P, et al. Butein downregulates chemokine receptor CXCR4 expression and function through suppression of NF-κB activation in breast and pancreatic tumor cells. Biochem Pharmacol. 2010;80:1553–62. [DOI] [PubMed]

71.

Shanmugam MK, Manu KA, Ong TH, Ramachandran L, Surana R, Bist P, et al. Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model. Int J Cancer. 2011;129:1552–63. [DOI] [PubMed]

72.

Siveen KS, Mustafa N, Li F, Kannaiyan R, Ahn KS, Kumar AP, et al. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model. Oncotarget. 2014;5:634–48. [DOI] [PubMed] [PMC]

73.

Wong ALA, Hirpara JL, Pervaiz S, Eu JQ, Sethi G, Goh BC. Do STAT3 inhibitors have potential in the future for cancer therapy? Expert Opin Investig Drugs. 2017;26:883–7. [DOI]

74.

Checker R, Sandur SK, Sharma D, Patwardhan RS, Jayakumar S, Kohli V, et al. Potent anti-inflammatory activity of ursolic acid, a triterpenoid antioxidant, is mediated through suppression of NF-κB, AP-1 and NF-AT. PLoS One. 2012;7:e31318. [DOI] [PubMed] [PMC]

75.

Yang Y, Ge PJ, Jiang L, Li FL, Zhu QY. Modulation of growth and angiogenic potential of oral squamous carcinoma cells in vitro using salvianolic acid B. BMC Complement Altern Med. 2011;11:54. [DOI] [PubMed] [PMC]

76.

Wei J, Xie G, Ge S, Qiu Y, Liu W, Lu A, et al. Metabolic transformation of DMBA-induced carcinogenesis and inhibitory effect of salvianolic acid B and breviscapine treatment. J Proteome Res. 2012;11:1302–16. [DOI] [PubMed]

77.

DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev. 2015;24:1495–506. [DOI] [PubMed]

78.

Shanmugam MK, Ahn KS, Hsu A, Woo CC, Yuan Y, Tan KHB, et al. Thymoquinone inhibits bone metastasis of breast cancer cells through abrogation of the CXCR4 signaling axis. Front Pharmacol. 2018;9:1294. [DOI] [PubMed] [PMC]

79.

Shin EM, Hay HS, Lee MH, Goh JN, Tan TZ, Sen YP, et al. DEAD-box helicase DP103 defines metastatic potential of human breast cancers. J Clin Invest. 2014;124:3807–24. [DOI] [PubMed] [PMC]

80.

Bhuvanalakshmi G, BasappaRangappa KS, Dharmarajan A, Sethi G, Kumar AP, et al. Breast cancer stem-like cells are inhibited by diosgenin, a steroidal saponin, by the attenuation of the Wnt β-catenin signaling via the Wnt antagonist secreted frizzled related protein-4. Front Pharmacol. 2017;8:124. [DOI] [PubMed] [PMC]

81.

Jia LY, Shanmugam MK, Sethi G, Bishayee A. Potential role of targeted therapies in the treatment of triple-negative breast cancer. Anticancer Drugs. 2016;27:147–55. [DOI] [PubMed]

82.

Parikh NR, Mandal A, Bhatia D, Siveen KS, Sethi G, Bishayee A. Oleanane triterpenoids in the prevention and therapy of breast cancer: current evidence and future perspectives. Phytochem Rev. 2014;13:793–810. [DOI] [PubMed] [PMC]

83.

Katary MA, Abdelsayed R, Alhashim A, Abdelhasib M, Elmarakby AA. Salvianolic acid B slows the progression of breast cancer cell growth via enhancement of apoptosis and reduction of oxidative stress, inflammation, and angiogenesis. Int J Mol Sci. 2019;20:5653. [DOI]

84.

Sha W, Zhou Y, Ling ZQ, Xie G, Pang X, Wang P, et al. Antitumor properties of Salvianolic acid B against triple-negative and hormone receptor-positive breast cancer cells via ceramide-mediated apoptosis. Oncotarget. 2018;9:36331–43. [DOI] [PubMed] [PMC]

85.

Fares N, Péron JM. Epidemiology, natural history, and risk factors of hepatocellular carcinoma. Rev Prat. 2013;63:216–7, 220–2. French. [PubMed]

86.

Rajendran P, Li F, Manu KA, Shanmugam MK, Loo SY, Kumar AP, et al. γ-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent. Br J Pharmacol. 2011;163:283–98. [DOI] [PubMed] [PMC]

87.

Dai X, Ahn KS, Wang LZ, Kim C, Deivasigamni A, Arfuso F, et al. Ascochlorin enhances the sensitivity of doxorubicin leading to the reversal of epithelial-to-mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther. 2016;15:2966–76. [DOI] [PubMed]

88.

Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol. 2014;20:4115–27. [DOI] [PubMed] [PMC]

89.

Sethi G, Chatterjee S, Rajendran P, Li F, Shanmugam MK, Wong KF, et al. Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. Mol Cancer. 2014;13:66. [DOI] [PubMed] [PMC]

90.

Swamy SG, Kameshwar VH, Shubha PB, Looi CY, Shanmugam MK, Arfuso F, et al. Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma. Target Oncol. 2017;12:1–10. [DOI] [PubMed]

91.

Dai X, Ahn KS, Kim C, Siveen KS, Ong TH, Shanmugam MK, et al. Ascochlorin, an isoprenoid antibiotic inhibits growth and invasion of hepatocellular carcinoma by targeting STAT3 signaling cascade through the induction of PIAS3. Mol Oncol. 2015;9:818–33. [DOI] [PubMed] [PMC]

92.

Mastron JK, Siveen KS, Sethi G, Bishayee A. Silymarin and hepatocellular carcinoma: a systematic, comprehensive, and critical review. Anticancer Drugs. 2015;26:475–86. [DOI] [PubMed]

93.

Mohan CD, Bharathkumar H, Bulusu KC, Pandey V, Rangappa S, Fuchs JE, et al. Development of a novel azaspirane that targets the Janus kinase–signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo. J Biol Chem. 2014;289:34296–307. [DOI] [PubMed] [PMC]

94.

Shi Y, Pan D, Yan L, Chen H, Zhang X, Yuan J, et al. Salvianolic acid B improved insulin resistance through suppression of hepatic ER stress in ob/ob mice. Biochem Biophys Res Commun. 2020;4:733–7. [DOI]

95.

Wang QL, Wu Q, Tao YY, Liu CH, El-Nezami H. Salvianolic acid B modulates the expression of drug-metabolizing enzymes in HepG2 cells. Hepatobiliary Pancreat Dis Int. 2011;10:502–8. [DOI] [PubMed]

96.

Wang M, Sun G, Wu P, Chen R, Yao F, Qin M, et al. Salvianolic acid B prevents arsenic trioxide-induced cardiotoxicity in vivo and enhances its anticancer activity in vitro. Evid Based Complement Alternat Med. 2013;2013:759483. [DOI] [PubMed] [PMC]

97.

Pai SI, Westra WH. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol. 2009;4:49–70. [DOI] [PubMed] [PMC]

98.

Selvi RB, Swaminathan A, Chatterjee S, Shanmugam MK, Li F, Ramakrishnan GB, et al. Inhibition of p300 lysine acetyltransferase activity by luteolin reduces tumor growth in head and neck squamous cell carcinoma (HNSCC) xenograft mouse model. Oncotarget. 2015;6:43806–18. [DOI] [PubMed] [PMC]

99.

Lee JH, Rangappa S, Mohan CD, BasappaSethi G, Lin ZX, et al. Brusatol, a Nrf2 inhibitor targets STAT3 signaling cascade in head and neck squamous cell carcinoma. Biomolecules. 2019;9:550. [DOI]

100.

Hsu PJ, Yan K, Shi H, Izumchenko E, Agrawal N. Molecular biology of oral cavity squamous cell carcinoma. Oral Oncol. 2020;102:104552. [DOI] [PubMed]

101.

Li F, Shanmugam MK, Chen L, Chatterjee S, Basha J, Kumar AP, et al. Garcinol, a polyisoprenylated benzophenone modulates multiple proinflammatory signaling cascades leading to the suppression of growth and survival of head and neck carcinoma. Cancer Prev Res (Phila). 2013;6:843–54. [DOI] [PubMed]

102.

Baek SH, Ko JH, Lee H, Jung J, Kong M, Lee JW, et al. Resveratrol inhibits STAT3 signaling pathway through the induction of SOCS-1: role in apoptosis induction and radiosensitization in head and neck tumor cells. Phytomedicine. 2016;23:566–77. [DOI] [PubMed]

103.

Zhao Y, Guo Y, Gu X. Salvianolic acid B, a potential chemopreventive agent, for head and neck squamous cell cancer. J Oncol. 2011;2011:534548. [DOI] [PubMed] [PMC]

104.

Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet. 2009;5:e1000676. [DOI] [PubMed] [PMC]

105.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. [DOI] [PubMed]

106.

Perrott S, Laurie K, Laws K, Johnes A, Miedzybrodzka Z, Samuel L. Young-onset colorectal cancer in the North East of Scotland: survival, clinico-pathological features and genetics. BMC Cancer. 2020;20:108. [DOI] [PubMed] [PMC]

107.

Guo P, Wang S, Liang W, Wang W, Wang H, Zhao M, et al. Salvianolic acid B reverses multidrug resistance in HCT-8/VCR human colorectal cancer cells by increasing ROS levels. Mol Med Rep. 2017;15:724–30. [DOI] [PubMed] [PMC]

108.

Guo P, Wang J, Gao W, Liu X, Wu S, Wan B, et al. Salvianolic acid B reverses multidrug resistance in nude mice bearing human colon cancer stem cells. Mol Med Rep. 2018;18:1323–34. [DOI] [PubMed] [PMC]

109.

Bhuvanalakshmi G, Gamit N, Patil M, Arfuso F, Sethi G, Dharmarajan A, et al. Stemness, pluripotentiality, and Wnt antagonism: sFRP4, a Wnt antagonist mediates pluripotency and stemness in glioblastoma. Cancers (Basel). 2018;11:25. [DOI]

110.

Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol Mech Dis. 2014;9:1–25. [DOI]

111.

Wang ZS, Luo P, Dai SH, Liu ZB, Zheng XR, Chen T. Salvianolic acid B induces apoptosis in human glioma U87 cells through p38-mediated ROS generation. Cell Mol Neurobiol. 2013;33:921–8. [DOI] [PubMed]

112.

Chen W, Wang N, Li RC, Xu GF, Bao G, Jiang HT, et al. Salvianolic acid B renders glioma cells more sensitive to radiation via Fis-1-mediated mitochondrial dysfunction. Biomed Pharmacother. 2018;107:1230–6. [DOI] [PubMed]

113.

Ningegowda R, Shivananju NS, Rajendran P, BasappaRangappa KS, Chinnathambi A, et al. A novel 4,6-disubstituted-1,2,4-triazolo-1,3,4-thiadiazole derivative inhibits tumor cell invasion and potentiates the apoptotic effect of TNFα by abrogating NF-κB activation cascade. Apoptosis. 2017;22:145–57. [DOI] [PubMed]

114.

Webb PM, Green AC, Jordan SJ. Trends in hormone use and ovarian cancer incidence in US white and Australian women: implications for the future. Cancer Causes Control. 2017;28:365–70. [DOI] [PubMed]

115.

Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61:183–203. [DOI] [PubMed] [PMC]

116.

Aerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, Brisse H, Doz F, Desjardins L. Retinoblastoma. Orphanet J Rare Dis. 2006;1:31. [DOI] [PubMed] [PMC]

117.

Liu XA. Effects of salvianolic acid B on in vitro growth inhibition and apoptosis induction of retinoblastoma cells. Int J Ophthalmol. 2012;5:272–6 [DOI] [PubMed] [PMC]

118.

Sinha N, Panda PK, Naik PP, Das DN, Mukhopadhyay S, Maiti TK, et al. Abrus agglutinin promotes irreparable DNA damage by triggering ROS generation followed by ATM-p73 mediated apoptosis in oral squamous cell carcinoma. Mol Carcinog. 2017;56:2400–13. [DOI] [PubMed]

119.

Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45:309–16. [DOI] [PubMed]

120.

Behera AK, Kumar M, Shanmugam MK, Bhattacharya A, Rao VJ, Bhat A, et al. Functional interplay between YY1 and CARM1 promotes oral carcinogenesis. Oncotarget. 2019;10:3709–24. [DOI] [PubMed] [PMC]

121.

Sawhney M, Rohatgi N, Kaur J, Shishodia S, Sethi G, Gupta SD, et al. Expression of NF-κB parallels COX-2 expression in oral precancer and cancer: association with smokeless tobacco. Int J Cancer. 2007;120:2545–56. [DOI] [PubMed]

122.

Zhou ZT, Yang Y, Ge JP. The preventive effect of salvianolic acid B on malignant transformation of DMBA-induced oral premalignant lesion in hamsters. Carcinogenesis. 2006;27:826–32. [DOI] [PubMed]

123.

Wei J, Wu J, Xu W, Nie H, Zhou R, Wang R, et al. Salvanic acid B inhibits glycolysis in oral squamous cell carcinoma via targeting PI3K/AKT/HIF-1α signaling pathway. Cell Death Dis. 2018;9:599. [DOI] [PubMed] [PMC]

124.

Tao L, Wang S, Zhao Y, Sheng X, Wang A, Zheng S, et al. Phenolcarboxylic acids from medicinal herbs exert anticancer effects through disruption of COX-2 activity. Phytomedicine. 2014;21:1473–82. [DOI] [PubMed]

125.

Guo L, Lei CK, Shan M. Study of growth inhibitory effect and apoptosis induced by different matches of Tanshinone IIA and Salvianolic acid B on acute promyelocytic leukemia cells (HL-60). Zhong Yao Cai. 2008;31:1512–4. Chinese. [PubMed]

126.

Libring S, Shinde A, Chanda MK, Nuru M, George H, Saleh AM, et al. The dynamic relationship of breast cancer cells and fibroblasts in fibronectin accumulation at primary and metastatic tumor sites. Cancers (Basel). 2020;12:1270. [DOI]

127.

Uzunalli G, Dieterly AM, Kemet CM, Weng HY, Soepriatna AH, Goergen CJ, et al. Dynamic transition of the blood-brain barrier in the development of non-small cell lung cancer brain metastases. Oncotarget. 2019;10:6334–48. [DOI] [PubMed] [PMC]

128.

Shinde A, Hardy SD, Kim D, Akhand SS, Jolly MK, Wang WH, et al. Spleen tyrosine kinase-mediated autophagy is required for epithelial-mesenchymal plasticity and metastasis in breast cancer. Cancer Res. 2019;79:1831–43. [DOI] [PubMed] [PMC]

129.

Shinde A, Paez JS, Libring S, Hopkins K, Solorio L, Wendt MK. Transglutaminase-2 facilitates extracellular vesicle-mediated establishment of the metastatic niche. Oncogenesis. 2020;9:16. [DOI] [PubMed] [PMC]

130.

Shinde A, Libring S, Alpsoy A, Abdullah A, Schaber JA, Solorio L, et al. Autocrine fibronectin inhibits breast cancer metastasis. Mol Cancer Res. 2018;16:1579–89. [DOI] [PubMed] [PMC]

131.

Shinde A, Wilmanski T, Chen H, Teegarden D, Wendt MK. Pyruvate carboxylase supports the pulmonary tropism of metastatic breast cancer. Breast Cancer Res. 2018;20:76. [DOI] [PubMed] [PMC]

132.

Hardy SD, Shinde A, Wang WH, Wendt MK, Geahlen RL. Regulation of epithelial-mesenchymal transition and metastasis by TGF-β, P-bodies, and autophagy. Oncotarget. 2017;8:103302–14. [DOI] [PubMed] [PMC]

133.

Wilmanski T, Zhou X, Zheng W, Shinde A, Donkin SS, Wendt M, et al. Inhibition of pyruvate carboxylase by 1α,25-dihydroxyvitamin D promotes oxidative stress in early breast cancer progression. Cancer Lett. 2017;411:171–81. [DOI] [PubMed] [PMC]

134.

Luo P, Tan Z, Zhang Z, Li H, Mo Z. Inhibitory effects of salvianolic acid B on the high glucose-induced mesangial proliferation via NF-κB-dependent pathway. Bio Pharm Bull. 2008;31:1381–6. [DOI] [PubMed]

135.

Yu F, Lu Z, Chen B, Wu X, Dong P, Zheng J. Salvianolic acid B-induced microRNA-152 inhibits liver fibrosis by attenuating DNMT 1-mediated Patched1 methylation. J Cell Mol Med. 2015;19:2617–32. [DOI] [PubMed] [PMC]

136.

Tang Q, Zhong H, Xie F, Xie J, Chen H, Yao G. Expression of miR-106b-25 induced by salvianolic acid B inhibits epithelial-to-mesenchymal transition in HK-2 cells. Eur J Pharmacol. 2014;741:97–103. [DOI] [PubMed]

137.

Wang QL, Tao YY, Yuan JL, Shen L, Liu CH. Salvianolic acid B prevents epithelial-to-mesenchymal transition through the TGF-β1 signal transduction pathway in vivo and in vitro. BMC Cell Biol. 2010;11:31. [DOI] [PubMed] [PMC]

138.

Li J, Zhang C, He W, Qiao H, Chen J, Wang K, et al. Coordination-driven assembly of catechol-modified chitosan for the kidney-specific delivery of salvianolic acid B to treat renal fibrosis. Biomater Sci. 2017;6:179–88. [DOI] [PubMed]

139.

Brabletz T. EMT and MET in metastasis: where are the cancer stem cells? Cancer cell. 2012;22:699–701. [DOI] [PubMed]

140.

Kunnumakkara AB, Harsha C, Banik K, Vikkurthi R, Sailo BL, Bordoloi D, et al. Is curcumin bioavailability a problem in humans: lessons from clinical trials. Expert Opin Drug Metab Toxicol. 2019;15:705–33. [DOI] [PubMed]

141.

Zhang J, Yu H, Sheng Y, Li L, Ye M, Guo D. HPLC determination and pharmacokinetic studies of salvianolic acid B in rat plasma after oral administration of Radix Salviae miltiorrhizae extract. Biomed Chromatogr. 2005;19:15–8. [DOI] [PubMed]

142.

Gao DY, Han LM, Zhang LH, Fang XL, Wang JX. Bioavailability of salvianolic acid B and effect on blood viscosities after oral administration of salvianolic acids in beagle dogs. Arch Pharm Res. 2009;32:773–9. [DOI] [PubMed]

143.

Zhan Y, Xu JP, Liang JB, Sheng LS, Xiang BR, Zou QG, et al. Simultaneous LC-MS-MS analysis of danshensu, salvianolic acid B, and hydroxysafflor yellow A in beagle dog plasma, and application of the method to a pharmacokinetic study of danhong lyophilized powder for injection. Chromatographia. 2008;68:71–9. [DOI]

144.

Li X, Cheng C, Wang F, Huang Y, Jia W, Olaleye OE, et al. Pharmacokinetics of catechols in human subjects intravenously receiving XueBiJing injection, an emerging antiseptic herbal medicine. Drug Metab Pharmacokinet. 2016;31:95–8. [DOI] [PubMed]

145.

Guo X, Chen X, Li L, Shen Z, Wang X, Zheng P, et al. LC-MS determination and pharmacokinetic study of six phenolic components in rat plasma after taking traditional Chinese medicinal-preparation: Guanxinning lyophilized powder for injection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;873:51–8. [DOI]

146.

Huang B, Li G, Guo YF, Wang SS, Liu F, Xu HY, et al. Study on absorption location of four components from Naoxintong capsule. Zhongguo Zhong Yao Za Zhi. 2013;38:889–93. Chinese. [PubMed]

147.

Zhou L, Chow MSS, Zuo Z. Effect of sodium caprate on the oral absorptions of danshensu and salvianolic acid B. Int J Pharm. 2009;379:109–18. [DOI] [PubMed]

148.

Wu YT, Chen YF, Hsieh YJ, Jaw I, Shiao MS, Tsai TH. Bioavailability of salvianolic acid B in conscious and freely moving rats. Int J Pharm. 2006;326:25–31. [DOI] [PubMed]

149.

Grossi C, Guccione C, Isacchi B, Bergonzi MC, Luccarini I, Casamenti F, et al. Development of blood-brain barrier permeable nanoparticles as potential carriers for salvianolic acid B to CNS. Planta Med. 2017;83:382–91. [DOI] [PubMed]

150.

Qi Q, Hao K, Li FY, Cao LJ, Wang GJ, Hao HP. The identification and pharmacokinetic studies of metabolites of salvianolic acid B after intravenous administration in rats. Chin J Nat Med. 2013;11:560–5. [DOI] [PubMed]

151.

Lai XJ, Zhang L, Li JS, Liu HQ, Liu XH, Di LQ, et al. Comparative pharmacokinetic and bioavailability studies of three salvianolic acids after the administration of Salviae miltiorrhizae alone or with synthetical borneol in rats. Fitoterapia. 2011;82:883–8. [DOI] [PubMed]

152.

Abdelkawy KS, Lack K, Elbarbry F. Pharmacokinetics and pharmacodynamics of promising arginase inhibitors. Eur J Drug Metab Pharmacokinet. 2017;42:355–70. [DOI] [PubMed]

153.

He Q, Zhang J, Chen F, Guo L, Zhu Z, Shi J. An anti-ROS/hepatic fibrosis drug delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles. Biomaterials. 2010;31:7785–96. [DOI] [PubMed]

154.

Peng Q, Gong T, Zuo J, Liu J, Zhao D, Zhang Z. Enhanced oral bioavailability of salvianolic acid B by phospholipid complex loaded nanoparticles. Pharmazie. 2008;63:661–6. [PubMed]

155.

Zhang CY, Zhang H, Dong Y, Ren WG, Chen HW. Study on compatibility of Salviae Miltiorrhizae Radix et Rhizoma and Chuanxiong Rhizoma based on pharmacokinetics of effective components salvianolic acid B and ferulic acid in rat plasma. Zhongguo Zhong Yao Za Zhi. 2015;40:1589–93. Chinese. [PubMed]

156.

Qiu F, Zhang R, Sun J, Jiye A, Hao H, Peng Y, et al. Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab Dispos. 2008;36:1308–14. [DOI] [PubMed]

157.

Qin CZ, Ren X, Zhou HH, Mao XY, Liu ZQ. Inhibitory effect of salvianolate on human cytochrome P450 3A4 in vitro involving a noncompetitive manner. Int J Clin Exp Med. 2015;8:15549–55. [PubMed] [PMC]

158.

Ding L, Li J, Huang R, Liu Z, Li C, Yao S, et al. Salvianolic acid B protects against myocardial damage caused by nanocarrier TiO2; and synergistic anti-breast carcinoma effect with curcumin via codelivery system of folic acid-targeted and polyethylene glycol-modified TiO2 nanoparticles. Int J Nanomedicine. 2016;11:5709–27. [DOI] [PubMed] [PMC]

159.

Si Y, Li N, Tong L, Lin B, Wang W, Xing Y, et al. Bioactive minor components of the total salvianolic acids injection prepared from Salvia miltiorrhiza Bge. Bioorganic Med Chem Lett. 2016;26:82–6. [DOI]

160.

Xie X, Sun W, Miao J, Huang J, Xu J, Liu X, et al. Development and validation of a UFLC-MS/MS method for determination of 7′(Z)-(8″S, 8‴S)-epi-salvianolic acid E, (7′R, 8′R, 8″S, 8‴S)-epi-salvianolic acid B and salvianolic acid B in rat plasma and its application to pharmacokinetic studies. J Chromatogr B. 2016;1022:6–12. [DOI]

161.

Zhao Q, Yang M, Deng Y, Yu H, Wang L, Teng F, et al. The safety evaluation of salvianolic acid B and ginsenoside Rg1 combination on mice. Int J Mol Sci. 2015;16:29345–56. [DOI] [PubMed] [PMC]

162.

Adams JD, Wang R, Yang J, Lien EJ. Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditions. Chin Med. 2006;1:3. [DOI] [PubMed] [PMC]